ROME (EGMN) – Tapentadol extended release, an investigational centrally acting analgesic, proved effective both for moderate to severe diabetic peripheral neuropathy and for similarly severe chronic nociceptive pain due to osteoarthritis or low-back injury in a series of five phase III clinical trials.
